Hepatocellular carcinoma (See: Liver cancer)
Make an Appointment
Talk to DoctorOverview
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, originating directly within the main structural tissue of the liver, specifically in a type of cell known as a hepatocyte (liver cell). Unlike metastatic cancers that spread to the liver from other organs, HCC usually emerges in the context of underlying chronic liver disease, most notably as a complication of severe liver scarring known as cirrhosis or chronic infections from the hepatitis B or C viruses. Because this disease is frequently completely asymptomatic in its early stages, it is most commonly detected during routine screening or health checkups rather than through obvious warning signs. Recognizing HCC distinctively is crucial, as its trajectory and management significantly diverge from other cancer types.
Symptoms
- Often completely asymptomatic in early stages (frequently found only during routine surveillance).
- Unintentional weight loss.
- Loss of appetite or feeling unusually full after eating very little.
- Upper abdominal pain, particularly on the right side.
- A noticeable lump, growth, or swelling in the abdomen.
- Jaundice (a yellowing of the skin and the whites of the eyes caused by a buildup of bilirubin).
- Worsening of pre-existing symptoms in patients with underlying cirrhosis.
Causes
- DNA Mutations: Changes in the DNA of hepatocytes cause them to bypass normal life cycles, multiplying uncontrollably and refusing to die when healthy cells would.
- Tumor Formation: The unchecked multiplication of these mutated cells forms a cancerous mass or tumor that can invade nearby blood vessels and healthy tissue.
- Viral Triggers: Chronic infection with the hepatitis B virus (HBV) or hepatitis C virus (HCV) is a primary biological driver of the cellular changes that lead to HCC.
- Severe Scarring: Cirrhosis creates an inflammatory, damaged environment in the liver that is highly susceptible to cancerous mutations.
- Unknown Origins: In rare cases, HCC develops in individuals with no underlying liver disease or clear viral cause, though the exact biological mechanism for this remains unclear.
Risk Factors
- Chronic Viral Hepatitis: Long-term, ongoing infection with HBV or HCV significantly elevates the risk of developing HCC.
- Cirrhosis: Progressive, irreversible liver scarring from various causes is the most common precursor to this type of cancer.
- Metabolic and Fatty Liver Conditions: Excess fat in the liver (metabolic dysfunction-associated steatotic liver disease) strongly increases risk, even without alcohol use.
- Excessive Alcohol Consumption: Long-term, heavy drinking contributes to irreversible liver damage and heightens the chance of mutations.
- Underlying Health Conditions: Being an older adult, having diabetes, or living with obesity can increase a person’s susceptibility.
- Environmental Toxins: Exposure to aflatoxins, poisons produced by certain molds on poorly stored crops like grains and nuts, is a known risk factor.
- Inherited Liver Diseases: Genetic conditions that run in families, such as hemochromatosis and Wilson’s disease.
- Cigarette Smoking: Smoking tobacco is linked to an increased risk of developing HCC.
Prevention
- Get Vaccinated: Receiving the hepatitis B vaccine is a primary, highly effective defense against viral-induced liver cancer.
- Prevent Cirrhosis: Limiting or completely avoiding alcohol consumption prevents the severe liver scarring that frequently precedes HCC.
- Manage Weight and Metabolism: Maintaining a healthy weight through diet and exercise helps prevent fatty liver disease, an increasingly common pathway to liver cancer.
- Practice Safe Habits: Using protection during sexual intercourse and avoiding shared or unsterilized needles can prevent the transmission of hepatitis C, for which there is currently no vaccine.
- Seek Antiviral Treatment: If already infected with HBV or HCV, seeking specialized antiviral treatments can halt liver damage and significantly lower the risk of cancer development.
Diagnosis
- Routine Surveillance: Because HCC is often asymptomatic, high-risk patients (those with cirrhosis or chronic hepatitis) undergo regular screening, typically every six months, using abdominal ultrasounds to look for nodules.
- Blood Tests: Healthcare providers test for elevated levels of alpha-fetoprotein (AFP), a tumor marker that can indicate the presence of liver cancer when combined with imaging.
- Advanced Imaging Tests: Dynamic contrast-enhanced MRI or multi-phase CT scans are used to get a detailed view of the liver. Doctors use a standardized system called LI-RADS to grade lesions based on size and blood flow patterns, often allowing them to definitively diagnose HCC without needing a physical tissue sample.
- Liver Biopsy: While imaging is usually sufficient for a diagnosis, a doctor may remove a small sample of liver tissue for laboratory testing if the imaging results are inconclusive, or if the tumor appears in a liver that does not have cirrhosis.
Treatment
- Surgical Resection: Unlike many other cancers, traditional chemotherapy is rarely the primary treatment. For early-stage tumors in patients with well-preserved liver function, surgeons may perform a partial hepatectomy to completely remove the cancerous tissue along with a margin of healthy liver.
- Liver Transplantation: In cases where the tumor meets specific size criteria but the underlying liver is failing due to severe cirrhosis, replacing the entire diseased liver with a healthy donor organ offers the highest chance of a cure.
- Local Ablation: For small tumors, especially when surgery isn’t an option, doctors use targeted extreme heat (radiofrequency or microwave ablation) to destroy the cancer cells directly at the site.
- Transarterial Therapies: Treatments like transarterial chemoembolization (TACE) or radioembolization (TARE) are used for intermediate stages. They work by blocking the tumor’s specific blood supply and delivering concentrated, localized medication or radiation directly into the tumor, differing greatly from systemic chemotherapy.
- Systemic Immunotherapy and Targeted Therapy: For advanced HCC that cannot be treated with surgery or ablation, standard chemo is not the standard of care. Instead, doctors utilize immunotherapy combinations (which activate the patient’s immune system to fight the cancer) or targeted therapies (medications that block the specific abnormal pathways that allow liver cancer cells to survive).
